Therapies modulating insulin resistance in Parkinson’s disease: A cross talk
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 749, 135754
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Exenatide and the treatment of patients with Parkinson’s diseaseJournal of Clinical Investigation, 2013
- PINK1- and Parkin-mediated mitophagy at a glanceJournal of Cell Science, 2012
- Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's diseaseBrain, 2011
- Coffee consumption and the incidence of type 2 diabetes in men and women with normal glucose tolerance: The Strong Heart StudyNutrition, Metabolism and Cardiovascular Diseases, 2011
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's DiseaseCell, 2011
- Hypothalamic neurosphere progenitor cells in low birth-weight rat newborns: Neurotrophic effects of leptin and insulinBrain Research, 2011
- Exercise protects against MPTP-induced neurotoxicity in miceBrain Research, 2010
- Glycogen synthase kinase 3β mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1Journal of Endocrinology, 2010
- The Effect of Exercise Training in Improving Motor Performance and Corticomotor Excitability in People With Early Parkinson's DiseaseArchives of Physical Medicine and Rehabilitation, 2008
- PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3Nature Medicine, 2004